Back to All Collaborations

Finding new treatments for cryptosporidiosis

Active Since: 2012

Contributing to SDGs…

This collaborative project is focused on identifying and progressing lead compounds with potential to treat cryptosporidiosis.

MEMBER COMPANIES

PARTNER ORGANISATIONS

  • Academia or research institute

    University of Washington

Objectives

Identify potential new treatments for cryptosporidiosis.

Cryptosporidiosis is a parasitic disease that causes watery diarrhea. It occurs around the world, but is more common in developing countries and primarily affects children and their caregivers, older adults and people who are malnourished or immunocompromised. In developing countries, cryptosporidiosis in early childhood may be associated with subsequent impaired physical and cognitive development.

AbbVie is collaborating with the University of Washington Department of Public Health to study certain Bumped Kinase Inhibitors (BKIs) for safety and efficacy for treating the diseases caused by Cryptosporidium in humans and livestock.

SDGs THE PARTNERSHIP CONTRIBUTES TO

SDG 3: Good Health and Wellbeing

  1. 3.3: Communicable Diseases & NTDs

SDG 9: Industry Innovation and Infrastructure

SDG 17: Partnerships for the Goals 

RESULTS & MILESTONES

Lead compounds have been optimized to avoid safety and toxicity liabilities. Identification of a potential clinical candidate is in progress.